SeaTown Holdings’s BioMarin Pharmaceuticals BMRN Stock Holding History

SeaTown Holdings’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-122,175	Closed	-$10.4M	–	65
2022 Q3	$10.4M	Hold	122,175	–	–	1.58%	21
2022 Q2	$10.1M	Sell	122,175 -225,799	-65%	-$18M	2.19%	15
2022 Q1	$26.8M	Buy	347,974 +263,328	+311%	+$22M	1.99%	19
2021 Q4	$7.48M	Buy	+84,646	New	+$6.98M	0.4%	54
2017 Q4	–	Sell	-16,934	Closed	-$1.58K	–	55
2017 Q3	$1.58K	Sell	16,934 -5,066	-23%	-$448K	0.11%	53
2017 Q2	$2M	Buy	+22,000	New	+$2M	0.28%	44
2017 Q1	–	Sell	-32,800	Closed	-$2.72M	–	42
2016 Q4	$2.72M	Buy	+32,800	New	+$2.82M	0.63%	24

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

SeaTown Holdings's BMRN Position: Q4 2022 in Review

SeaTown Holdings sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2022, closing a stake of 122,175 shares — an estimated $10.4M sold.

SeaTown Holdings first reported a position in BMRN in Q4 2016 and held it in 7 quarters. The position peaked at $26.8M in Q1 2022. 581 funds tracked by Wall St. Rank hold BMRN as of Q4 2022.

SeaTown Holdings reported no remaining BioMarin Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
SeaTown Holdings sold 122,175 BioMarin Pharmaceuticals shares in Q4 2022, an estimated $10.4M.
SeaTown Holdings first reported a position in BioMarin Pharmaceuticals in Q4 2016 and held it in 7 quarters.
SeaTown Holdings's BioMarin Pharmaceuticals position peaked at $26.8M in Q1 2022.
581 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2022.

Based on SeaTown Holdings's 13F filing for Q4 2022, filed 13 Feb 2023.